AJMC

Primary Care Diabetes Bundle Management: 3-Year Outcomes for Microvascular and Macrovascular Events | Page 3

Published Online: June 26, 2014
Frederick J. Bloom Jr, MD; Xiaowei Yan, PhD; Walter F. Stewart, PhD; Thomas R. Graf, MD; Tammy Anderer, PhD; Duane E. Davis, MD; Steven B. Pierdon, MD; James Pitcavage, MS; and Glenn D. Steele Jr, MD
Prior evidence indicates that it is possible to improve process of care measures for diabetes in clinical practice, 30 and document small to modest improvements in glycemic control.31 There is a single report of reduced adverse events (amputations, retinopathy, and MI) using a diabetes disease management program.32 If substantiated, our findings that a DS reduces the microvascular and macrovascular complications of diabetes in only 3 years have potentially important implications for patients, providers, and payers. 33

Take-Away Points

A diabetes system of care using an all-or-none bundled measure can reduce the microvascular and macrovascular complications of diabetes in only 3 years.

  • A system of care for diabetes can reduce myocardial infarction, stroke, and retinopathy in only 3 years.

  • Translation into a workable care protocol in primary care is challenging. Workflows were developed that were measurable, scalable, reliable, and not dependent on the diligence of individual providers.

  • Payers and health systems can innovate and invest together in the infrastructure to build similar systems of care, knowing that the benefit for their patients with diabetes will be prompt.
Author Affiliations: Geisinger Health System, Danville, PA (FJB, TRG, TA, DED, SBP, GDS); Sutter Health, Sacramento, CA (XY, WFS, JP).

Source of Funding: Geisinger Health Plan.

Author Disclosures: Drs Bloom and Graf report accepting fees from the Merck Speaker’s Bureau. Dr Davis reports employment with a group practice that operates as part of Geisinger Health System, from which data were used as part of this study. The other authors (XY, WFS, TA, SBP, JP, GDS) report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.

Authorship Information: Concept and design (FJB, XY, WFS, TA, SBP, GDS); acquisition of data (FJB, XY, TA, SBP, JP, GDS); analysis and interpretation of data (FJB, XY, WFS, TA, JP, GDS); drafting of the manuscript (FJB, WFS, TA, DED, JP, GDS); critical revision of the manuscript for important intellectual content (FJB, XY, WFS, TA, DED, JP, GDS); statistical analysis (XY); obtaining funding (DED); administrative, technical, or logistic support (FJB, TA, SBP, JP, GDS); supervision (FJB, WFS, JP, GDS).

Address correspondence to: Frederick J. Bloom Jr, 100 N. Academy Ave, Danville, PA 17822-3836. E-mail: fbloom@geisinger.edu.
1. Health, United States, 2010: with special feature on death and dying. Report no. 2011-1232. National Center for Health Statistics: Hyattsville, MD; 2011.

2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.

3. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ. 2000;321(7258): 405-412.

4. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.

5. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.

6. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.

7. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-696.

8. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet. 2003;361(9374):2005-2016.

9. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressurelowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165(12):1410-1419.

10. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-591.

11. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115(1):114-126.

12. Rea TD, Heckbert SR, Kaplan RC, Smith NL, Lemaitre RN, Psaty BM. Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med. 2002;137(6):494-500.

13. American Diabetes Association. Standards of medical care in diabetes-- 2011. Diabetes Care. 2011;34(suppl 1):S11-S61.

14. Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United states, 1988-2002. Ann Intern Med. 2006;144(7):465-474.

15. Cebul RD, Love TE, Jain AK, Hebert CJ. Electronic health records and quality of diabetes care. N Engl J Med. 2011;365(9):825-833.

16. Weber V, Bloom F, Pierdon S, Wood C. Employing the electronic health record to improve diabetes care: a multifaceted intervention in an integrated delivery system. J Gen Intern Med. 2008;23(4):379-382.

17. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28(Suppl 1):S4-S36.

18. Bloom FJ, Jr, Graf T, Anderer T, Stewart WF. Redesign of a diabetes system of care using an all-or-none diabetes bundle to build teamwork and improve intermediate outcomes. Diabetes Spectrum. 2010;23(3):165-169.

19. HEDIS 2009. Volume 2: Technical Specifications. Washington, DC: NCQA; 2008: 134-137.

20. Roosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effect. Biometrika. 1983;70(1):41-55.

21. Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J. 2009;51(1):171-184.

22. Pencina MJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23(13):2109-2123.

23. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and decreased risk of stroke in women. JAMA. 1993;269(2):232-236.

24. Wolf PA, D’Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette smoking as a risk factor for stroke: the Framingham study. JAMA. 1988;259(7):1025-1029.

25. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359(9311):1004-1010.

26. Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) study. Eur Heart J. 2004;25(1):25-31.

27. Casalino LP. Which type of medical group provides higher-quality care? Ann Intern Med. 2006;145(11):860-861.

28. Shubrook JH,Jr, Snow RJ, McGill SL, Brannan GD. “All-or-none” (bundled) process and outcome indicators of diabetes care. Am J Manag Care. 2010;16(1):25-32.

29. Kelley E. All or none measurement: why we know so little about the comprehensiveness of care. Int J Qual Health Care. 2007;19(1):1-3.

30. Mangione CM, Gerzoff RB, Williamson DF, et al. The association between quality of care and the intensity of diabetes disease management programs. Ann Intern Med. 2006;145(2):107-116.

31. Shojania KG, Ranji SR, McDonald KM, et al. Effects of quality improvement strategies for type 2 diabetes on glycemic control: A metaregression analysis. JAMA. 2006;296(4):427-440. doi: 10.1001/jama .296.4.427.

32. Beaulieu N, Cutler DM, Ho K, et al. The business case for diabetes disease management for managed care organizations. Forum for Health Economics & Policy. 2006;9(1):1.

33. Paulus RA, Davis K, Steele GD. Continuous innovation in health care: implications of the Geisinger experience. Health Aff (Millwood). 2008;27(5):1235-1245.
Issue: June 2014
More on AJMC.COM